Related Experiment Video

Updated: Jul 7, 2026

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

Controversies in the management of hyperglycemia in the ELBW infant

V R Kairamkonda1, M Khashu

  • 1Neonatal Intensive Care Unit, Leicester Royal Infirmary, Leicester, LE1 5WW, UK.

Indian Pediatrics
|February 6, 2008
PubMed

Insights

Neonatal hyperglycemia is common in intensive care units, particularly for extremely low birth weight (ELBW) infants. Current evidence suggests benefits of control, but long-term effects of hyperglycemia and insulin therapy require further study.

Area of Science:

  • Neonatology
  • Pediatric Endocrinology
  • Intensive Care Medicine

Background:

  • Neonatal hyperglycemia is a frequent complication in intensive care settings.
  • Extremely low birth weight (ELBW) infants are particularly susceptible.
  • There is a significant lack of consensus regarding the definition, management, and implications of neonatal hyperglycemia.

Purpose of the Study:

  • To review the current evidence on the management of neonatal hyperglycemia.
  • To address the uncertainties surrounding optimal strategies and long-term outcomes.
  • To provide a pragmatic approach pending further research.

Main Methods:

  • Systematic review of existing literature on neonatal hyperglycemia.
  • Analysis of studies focusing on management strategies and clinical outcomes.
  • Evaluation of short-term and long-term implications in ELBW infants.

Main Results:

  • Adequate control of hyperglycemia shows potential benefits in neonates.
  • Long-term implications of both hyperglycemia and insulin therapy in ELBW infants remain largely unknown.
  • Existing evidence does not provide definitive guidance on optimal management.

Conclusions:

  • A pragmatic approach involves using an operational definition for hyperglycemia.
  • Insulin therapy should be judiciously applied, primarily in high-risk neonates prone to osmolar derangement.
  • Further research is crucial to elucidate the long-term consequences and refine management guidelines.

Related Concept Videos

Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
Hyperglycemia01:29

Hyperglycemia

Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility, suggesting a...
Hypoglycemia01:26

Hypoglycemia

Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...